In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares closed yesterday at $5.09, close to its 52-week low of $5.03.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.6% and a 39.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clearside Biomedical with a $29 average price target, a 469.7% upside from current levels. In a report issued on October 23, Wedbush also reiterated a Buy rating on the stock with a $29 price target.
.
See today’s analyst top recommended stocks >>
Based on Clearside Biomedical’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.7 million. In comparison, last year the company had a GAAP net loss of $18.34 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy.
